An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

被引:186
作者
Cocks, K.
Cohen, D.
Wisloff, F.
Sezerc, O.
Lee, S.
Hippe, E.
Gimsing, P.
Turesson, I.
Hajek, R.
Smith, A.
Graham, L.
Phillips, A.
Stead, M.
Velikova, G.
Brown, J.
机构
[1] Univ Leeds, Clin Trials Res Unit, Leeds LS2 9NG, W Yorkshire, England
[2] Univ Oslo, Ulleval Univ Hosp, Dept Haematol, N-0316 Oslo, Norway
[3] Univ Oslo, Fac Med, N-0316 Oslo, Norway
[4] Univ Hosp Charite Berlin, Dept Hematol & Oncol, Berlin, Germany
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Herlev Hosp, Dept Haematol, DK-2730 Herlev, Denmark
[7] Rigshosp, Dept Haematol, DK-2100 Copenhagen, Denmark
[8] Malmo Univ Hosp, Malmo, Sweden
[9] MU Brno, Fac Med, Brno, Czech Republic
[10] Fac Hosp Brno, Dept Internal Med & Hematooncol, Brno, Czech Republic
[11] Southampton Gen Hosp, Southampton SO9 4XY, Hants, England
[12] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England
关键词
quality of life; multiple myeloma; validation; questionnaires; QLQ-C30; QLQ-MY24; QLQ-MY20;
D O I
10.1016/j.ejca.2007.04.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To test the reliability, validity and sensitivity of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-MY24 questionnaire, designed to assess the quality of life of myeloma patients with the QLQ-C30. Methods: The study was carried out through the EORTC Quality of Life Group using clinical trials in seven countries. All trials used the QLQ-C30 and QLQ-MY24 at baseline and a follow-up timepoint. Results: Two hundred and forty patients participated. The questionnaires were acceptable to patients. The hypothesised scale structure (disease symptoms, side-effects, body image and future perspective) was confirmed by multi-trait scaling, internal consistency and correlation analysis. Most scales demonstrated sensitivity to change and discriminated between clinically different patients. The social support scale (4 items) was removed due to observed ceiling effects. Conclusion: The final questionnaire contains 20 items, QLQ-MY20, and is a reliable and valid instrument recommended for use with the QLQ-C30 in myeloma patients. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1670 / 1678
页数:9
相关论文
共 13 条
[1]  
CHRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P296
[2]  
CULL A, 1998, BEHALF EORTC QUALITY
[3]  
Hays R., 1988, USERS GUIDE MULTITRA
[4]  
HAYS RD, P 17 ANN SAS US GROU
[5]   Drug therapy: Multiple myeloma [J].
Kyle, RA ;
Rajkumar, SV .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (18) :1860-1873
[6]  
Nunnally JC, 1978, PSYCHOMETRIC THEORY, V2nd
[7]  
*SAS I INC, 2000, SAS CARY NC
[8]  
SELBY P, 1996, OXFORD TXB ONCOLOGY, P1852
[9]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER APPROACH TO QUALITY-OF-LIFE ASSESSMENT - GUIDELINES FOR DEVELOPING QUESTIONNAIRE MODULES [J].
SPRANGERS, MAG ;
CULL, A ;
BJORDAL, K ;
GROENVOLD, M ;
AARONSON, NK .
QUALITY OF LIFE RESEARCH, 1993, 2 (04) :287-295
[10]   Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma [J].
Stead, ML ;
Brown, JM ;
Velikova, G ;
Kaasa, S ;
Wisloff, F ;
Child, JA ;
Hippe, E ;
Hjorth, M ;
Sezer, O ;
Selby, P .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (03) :605-611